Reblozyl is the first and only therapy to demonstrate superiority compared to an erythropoiesis stimulating agent (ESA) in MDS-related anemia
Dr. Laurent Leksell, Elekta’s Founder and Chairman of the Board, and IAEA’s Director General, Dr. Rafael Mariano Grossi meet in Stockholm to discuss reducing the global cancer burden
KEYTRUDA is the first immunotherapy approved in the EU for the first-line treatment of this patient population
Novo Nordisk’s GLP-1 Ozempic has reported a YoY increase in revenue from $2.1 billion to $3.2 billion
First PARP inhibitor approved in Japan to demonstrate clinically meaningful benefits in combination with a new hormonal agent
India will account for about 18% of the Asia-Pacific (APAC) MRI systems market in 2023
NIH’s candidate is based on the Adenovirus 4 backbone, largely used as a vector candidate in HIV and influenza vaccine clinical trials
The deal represents a total transaction value of up to $36 million with an initial upfront consideration of $14 million
Weinand is the former CEO and Chairman of the Board at Bayer Pharma AG, leading Bayer’s fully integrated $20 billion healthcare business
Oteseconazole Capsules were found to be safe and more effective than fluconazole
Subscribe To Our Newsletter & Stay Updated
